The Medicare GLP-1 Bridge lets certain Medicare beneficiaries obtain an eligible Wegovy, Zepbound or Foundayo product for $50 per 28- or 30-day supply. It runs from July 1, 2026, through December 31, 2027. You need qualifying Part D coverage, must meet defined medical criteria and must receive prior authorization. The benefit isn’t regular Part D coverage.
Who qualifies for the Medicare GLP-1 Bridge?
Enrollment alone isn’t enough. You must be at least 18, have Medicare Part D through a standalone prescription drug plan or an eligible Medicare Advantage plan with drug coverage, and use the medicine for weight reduction or maintenance. Certain plan arrangements are excluded unless you also carry a standalone Part D plan.
CMS also requires that your Part D plan hasn’t previously paid for a GLP-1 drug for you. The agency hadn’t determined the relevant Part D lookback period for 2027 as of November 6, 2026, so people applying that year may need updated guidance.
You must meet one of these clinical pathways:
- BMI of 35 or higher.
- BMI of 30 or higher plus heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or above.
- BMI of 27 or higher plus prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease.
CMS defines uncontrolled high blood pressure here as a reading above 140/90 despite concurrent treatment with two blood-pressure medicines. A single high reading or treatment with one medicine doesn’t match that specific program definition.
Eligibility rules aren’t the same as medical suitability. Your prescriber still needs to consider your health history, current medicines and the risks of a particular GLP-1 treatment. If you’re pregnant, have chronic disease or develop symptoms while using one, seek advice from a qualified clinician rather than changing treatment yourself.
Who doesn’t qualify?
The Medicare GLP-1 Bridge excludes people with type 2 diabetes, moderate-to-severe obstructive sleep apnea, or fatty liver disease known as metabolic dysfunction-associated steatohepatitis, or MASH. That may sound backward, but CMS’s reason is administrative: GLP-1 treatment for those conditions may be pursued through Part D rather than through this demonstration.
You also won’t qualify if your Part D plan previously paid for a GLP-1 drug, if you lack an eligible drug plan or if you don’t meet a listed BMI-and-condition pathway. A prescription by itself doesn’t establish eligibility.
Federal law generally excludes drugs used for weight loss from the definition of a Part D drug. The Bridge creates a temporary route around that exclusion; it doesn’t rewrite standard Part D policy. For a broader explanation of indication-specific payment, see our guide to insurance coverage for Ozempic and Wegovy.
Covered drugs, formulations and price comparisons
Three brands are included, but the formulation matters. Wegovy injections and tablets qualify in all dose strengths. Zepbound qualifies only as a KwikPen, meaning its single-dose pens and vials aren’t included. Foundayo, whose active ingredient is orforglipron, qualifies as a tablet.
| Bridge drug | Maker | Eligible form | 2026 manufacturer-listed self-pay price per supply | Bridge payment |
|---|---|---|---|---|
| Wegovy | Novo Nordisk | Injection or tablet; all strengths | Tablet: $149–$299; pen: $199 introductory, then $349–$399 | $50 |
| Zepbound | Eli Lilly | KwikPen only | $299–$699 per 28 days | $50 |
| Foundayo | Eli Lilly | Tablet | $149–$299 | $50 |
Manufacturer self-pay programs have terms and can change, so these figures are comparisons rather than guaranteed alternatives. They do show the scale of the difference. Against a $699 Zepbound KwikPen price, for example, the Medicare GLP-1 Bridge reduces the listed payment by $649 for one 28-day supply.
Price headlines can hide formulation restrictions. Honestly, that detail matters more than many summaries admit: a Zepbound prescription written for a vial or single-dose pen doesn’t become eligible merely because the brand name is covered. Our reporting on why GLP-1 medicines cost so much explains the wider pricing context.
What the $50 payment does and doesn’t cover
Under the Medicare GLP-1 Bridge, you pay a flat $50 for each eligible 28- or 30-day supply, regardless of dose or your current Part D benefit phase. Twelve supplies would cost $600, while 18 supplies would total $900. The second calculation illustrates continuous monthly use across the demonstration’s full July 2026 through December 2027 window, though actual refill timing may differ.
The payment stays outside your normal Part D accounting. It doesn’t satisfy your Part D deductible and doesn’t count toward TrOOP, the spending total used for the Part D out-of-pocket limit. Low-Income Subsidy assistance, commonly called Extra Help, can’t reduce the Bridge copay either.
Those exclusions are easy to miss. If you’re budgeting for several prescriptions, don’t assume each $50 payment moves you closer to the Part D spending cap. Our plain-language guide to deductibles, copays and insurance costs can help distinguish those separate calculations.
Every Medicare GLP-1 Bridge prescription requires prior authorization. The prescriber must certify that the medicine is being used as part of a diet-and-exercise lifestyle program and document the relevant BMI, condition and coverage criteria.
CMS’s 2026 prescriber guide says that after an eligible prescription claim, the pharmacy typically sends a prior-authorization request to the prescriber within 24 to 72 hours. That’s only the request, not the decision. CMS says approval or denial is communicated within 72 hours after the completed request is submitted.
Ask the pharmacy whether it sent the request, then ask the prescriber’s office whether it received and submitted it. That distinction can reveal where a stalled application sits. Our explanation of why prior authorization delays treatment covers the process and common paperwork gaps.
Once granted, Bridge authorization remains valid through December 31, 2027, including refills and dose changes. Switching to a different GLP-1 drug requires a new authorization. Continued approval also doesn’t promise that a pharmacy will have a product in stock.
A temporary program, not a permanent Part D benefit
The Medicare GLP-1 Bridge operates as a CMS demonstration outside the usual Part D coverage and payment flow. It began July 1, 2026, and CMS extended it through December 31, 2027, after deciding not to launch the BALANCE Model in 2027.
As of November 6, 2026, current CMS materials still listed that end date, and no substantive CMS change had been identified during the preceding 90 days. What happens in 2028 remains undecided. In my view, anyone starting treatment under a time-limited payment program should discuss a post-2027 affordability plan early rather than assume the $50 price will continue.
Keep the approval notice, prescription records and plan correspondence. If you change Part D or Medicare Advantage coverage, confirm that the new arrangement remains eligible before the next fill. The Bridge rules and ordinary Part D rules shouldn’t be treated as interchangeable.
Frequently asked questions
Does every Medicare member qualify for $50 Wegovy?
No. You need eligible Part D drug coverage, prior authorization and one of CMS’s BMI-and-condition pathways. Your plan also must not have previously paid for a GLP-1 drug for you.
Does Extra Help reduce the $50 GLP-1 copay?
No. Extra Help cost-sharing doesn’t apply to Bridge drugs, and the $50 payment doesn’t count toward your Part D deductible or out-of-pocket limit.
Is Zepbound covered in vials under the Bridge?
No. Only the Zepbound KwikPen is eligible. Single-dose pens and vials are excluded even when they contain the same brand-name medicine.
How long does Medicare GLP-1 Bridge approval take?
CMS says the pharmacy typically sends the request within 24 to 72 hours after the eligible claim, and a decision is communicated within 72 hours after submission. Missing records can extend the practical timeline.
Will the $50 price continue after 2027?
There is no confirmed continuation beyond December 31, 2027. Unless CMS or Congress announces another pathway, you shouldn’t assume the demonstration price will remain available in 2028.


